个性化文献订阅>期刊> Bioorganic & Medicinal Chemistry Letters
 

Novel heterocyclic DPP-4 inhibitors for the treatment of type 2 diabetes

  作者 Sutton, JM; Clark, DE; Dunsdon, SJ; Fenton, G; Fillmore, A; Harris, NV; Higgs, C; Hurley, CA; Krintel, SL; MacKenzie, RE; Duttaroy, A; Gangl, E; Maniara, W; Sedrani, R; Namoto, K; Ostermann, N; Gerhartz, B; Sirockin, F; Trappe, J; Hassiepen, U; Baeschlin, DK  
  选自 期刊  Bioorganic & Medicinal Chemistry Letters;  卷期  2012年22-3;  页码  1464-1468  
  关联知识点  
 

[摘要]Novel deazaxanthine-based DPP-4 inhibitors have been identified that are potent (IC50 < 10 nM) and highly selective versus other dipeptidyl peptidases. Their synthesis and SAR are reported, along with initial efforts to improve the PK profile through decoration of the deazaxanthine core. Optimisation of compound 3a resulted in the identification of compound (S)-4i, which displayed an improved in vitro and ADME profile. Further enhancements to the PK profile were possible by changing from the deazahypoxanthine to the deazaxanthine template, culminating in compound 12g, which displayed good ex vivo DPP-4 inhibition and a superior PK profile in rat, suggestive of once daily dosing in man. Crown Copyright (C) 2011 Published by Elsevier Ltd. All rights reserved.

 
      被申请数(0)  
 

[全文传递流程]

一般上传文献全文的时限在1个工作日内